Chou 2015 Fatty Acid Oxidation O2k-Network Discussion Forum: Difference between revisions

From Bioblast
(Created page with "{{Abstract |title=Chou 2015 Fatty Acid Oxidation O2k-Network Discussion Forum |info=[http://www.bioblast.at/index.php/Talk:Fatty_acid_oxidation O2k-Network Discussion Forum] |aut...")
 
No edit summary
 
(8 intermediate revisions by 3 users not shown)
Line 5: Line 5:
|year=2015
|year=2015
|event=Fatty Acid Oxidation O2k-Network Discussion Forum
|event=Fatty Acid Oxidation O2k-Network Discussion Forum
|abstract=
|abstract='''Protocol''': final concentration of digitonin in chamber is 10Ξg/ml
cell number in chamber is 2 millions cell/ml, cell type PBMC, Malate (2mM), Palmitoyl-DLcarnitine-HCl (20ΞM), ADP (2.5mM), pyruvate (5mM), glutamate (10mM), succinate (10mM), rotenone (0.1ΞM), malonic acid(5mM), myxothiazol (0.5ΞM), antimycin A (2.5ΞM), TMPD (0.5mM), azide (100mM)
|keywords=PBMC
}}
}}
{{Labeling
{{Labeling
|substratestates=FAO
|tissues=Blood cells, Lymphocyte, Platelet
|additional=Palmitoylcarnitine
|preparations=Permeabilized cells, Permeabilized tissue
|couplingstates=OXPHOS, ET
|pathways=F, N, S, NS, ROX
|additional=Palmitoylcarnitine, TW,
}}
}}

Latest revision as of 17:33, 25 February 2020

Chou 2015 Fatty Acid Oxidation O2k-Network Discussion Forum

Link: O2k-Network Discussion Forum

Chou Cheng-Hsien (2015)

Event: Fatty Acid Oxidation O2k-Network Discussion Forum

Protocol: final concentration of digitonin in chamber is 10Ξg/ml cell number in chamber is 2 millions cell/ml, cell type PBMC, Malate (2mM), Palmitoyl-DLcarnitine-HCl (20ΞM), ADP (2.5mM), pyruvate (5mM), glutamate (10mM), succinate (10mM), rotenone (0.1ΞM), malonic acid(5mM), myxothiazol (0.5ΞM), antimycin A (2.5ΞM), TMPD (0.5mM), azide (100mM)

â€Ē Keywords: PBMC


Labels:


Tissue;cell: Blood cells, Lymphocyte, Platelet  Preparation: Permeabilized cells, Permeabilized tissue 


Coupling state: OXPHOS, ET  Pathway: F, N, S, NS, ROX 


Palmitoylcarnitine, TW 

Cookies help us deliver our services. By using our services, you agree to our use of cookies.